A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Inclusion Criteria:

Patient (male or female) ≥12 years of age
ECOG (Eastern Cooperative Oncology Group) performance status ≤1
Must have progressed following standard therapy, or for whom, in the opinion of the Investigator, no effective standard therapy exists, is tolerated or appropriate.
Patients must be willing and able to undergo study required biopsies.
Presence of at least one measurable lesion according to RECIST v1.1.
Documented MAPK pathway alteration

Exclusion Criteria:

Prior treatment with ERK inhibitors.
History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO.
Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
Patients receiving proton pump inhibitors (PPI) which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study.
Patients with malignant disease other than that being treated in the study.
Clinically significant cardiac disease.

Other protocol-defined exclusion criteria may apply.